



Uscom

FY25 AGM Presentation

ASX: UCM

- Resolutions & Voting
- Overview, products and markets
- Milestones
- FY2025 Results
- FY2026 Drivers

Prof. Rob Phillips
Founder and Chairman,
Uscom Limited

Nov 27, 2025

USCOM Vision

World leading medical technology (ASX:UCM) with global footprint – Sydney, Singapore, Beijing, Budapest, London Delaware

- Cardiovascular and pulmonary devices
- Expanding product portfolio
- Digital technology
- Wireless connectivity

- Flagship science and technology in prestige cardiovascular and pulmonary sector.
- Multiple products with global regulatory
- Addressing diseases responsible for >75% of all mortality

- Foxconn manufacturing partnership to underwrite growth
- Chinese Foxconn domestic manufacturing, into global distribution
- High margin and >75 IP submissions

**~ 2000
Installed
USCOM 1A**

USCOM 1A units
installed globally

**> 75 IP
submissions**

IP submissions
protecting Uscom
technology

**> 20 years in
business**

>\$40m total receipts
over 10 years

**Sales into 52
countries**

Global clinical
adoption across
many applications

**> 1,200 peer
publications**

International peer
reviewed
publications



"Medical innovations for the World"



Non-invasive Medical Devices Improving Clinical Care And Patient Outcomes



USCOM 1A

Non-invasive Hemodynamic Monitor



Flagship digital Doppler device enabling real-time, non-invasive hemodynamic monitoring

- Provider of high-fidelity measurement and trending information on cardiovascular performance
- More accurate and cost-effective than invasive catheter-based hemodynamic monitoring
- Early detection and precision management of heart failure, systemic infections (e.g. sepsis, dengue), fluid guidance and hypertension
- Expanding clinical applications in preeclampsia and burn management



Central BP and Pulse Wave Analysis Monitor



Patented technology measuring central aortic pressure via upper arm cuff

- Emerging standard of care in hypertension, heart failure and vascular health
- Replaces conventional and widespread sub-systolic BP monitors (only 20% effective)
- BP+Home specialised device for home care hypertension and heart failure monitoring with digital cloud-based connectivity
- In International Space station and European space programme
- Recent China NMPA approval

SpiroSonic
Ultrasonic Spirometer



Digital ultrasonic spirometers for remote and in-clinic pulmonary monitoring

- Digital ultrasonic accuracy for pre/post-surgical monitoring of pulmonary functions and self-management
- Equipped with autodiagnosics, digital connectivity, and real-time patient feedback
- Real time lung function data for diagnosis and monitoring of asthma, COPD, occupational lung disease and pulmonary fibrosis
- Recent China NMPA approval






USCOM's Journey

- **1999**
 - Uscom Limited established
- **2003**
 - ASX listed – UCM
- **2010**
 - Successfully developed and clinically validated **USCOM1A**
 - Achieved sales approvals in the US, China, EU, Canada, and Asia-Pacific
- **2013**
 - Acquired Pulsecor to transform to **BP+** technologies
- **2015**
 - Acquired Thor Laboratories to transform to **SpiroSonic**
- **2017**
 - Critical USCOM evidence for **preeclampsia**
- **2018**
 - **Uscom China** established as National High Tech Enterprise by China Ministry of Science and Technology
- **2020**
 - Recommended in **Covid 19 treatment**
 - USCOM1A in **international Sepsis Guidelines for children**
- **2022**
 - Entered strategic partnership with **Foxconn**
- **2023**
 - Domestic manufacturing of USCOM devices approved in China
- **2024**
 - BP+ demonstrated as World Leading BP Monitor by ARTERY Validation
 - On going discussions with **China Resources Healthcare**
 - Signed strategic partnership with **Sinopharm**
- **2025**
 - Uscom became corporate member of AustCham China.
 - Received Break-through Technology Award from **Premier Health Group**
 - Established Uscom Training Facility at **West China hospital**

"Medical innovations for the World"



Global Footprint



Uscom - In The World's Best Hospitals



Operational Milestones



Sinopharm Partnership

- SinoPharm is one of China's largest medical device distributors and has signed a cooperative agreement with Uscom China for development of new marketing and sale initiatives. This collaboration will allow SinoPharm to diversify from principally pharmaceuticals to medical devices while providing Uscom access to SinoPharm's distribution and sales network being the third largest in the world.

Huaxi and University of Queensland

- Huaxi is China's largest and no 1 Hospital serving over 9,000 beds and providing >8M consultations and 2M telemetric consultations. Prof Phillips has opened the doors of collaboration between Huaxi and the University of Queensland and has now been appointed as a visiting Professor to Huaxi, one of the few foreigners appointed to the Hospital.


Prime Ministerial China Medtech Visit

- Prime Minister Anthony Albanese visited China to promote the new revitalized Australia and Chinese engagement with a focus on three major sectors; resources, food and agriculture and Medtech. Uscom featured at the Medtech meeting and made representation to the Prime Minister.



FY25 Results - Globally

UCM Total Receipts Trend FY12 – FY26*



\$2.58 million

Sale of Products



\$3.16 million

Total Revenue



25%

Down in Revenue

Building the future


Results

- Sale of products \$2.58m
- Revenue from ordinary activities down 25%, Sales declined in all regions except SE Asia, Cash on Hand \$967k
- **29% CAGR over 8yr** excluding 3 years of COVID and Russian war, plus 1 year of tariffs.
- **19% CAGR over 14yr** using FY26 mid sales forecasts and including 3 years of COVID and Russian war, plus 1 year of tariffs.




FY25 Results - Regionally

Uscom Total Revenue by Region



- Global platform for growth
- Hedged for currency and shifting geopolitics
- Global reporting, tax, transfer pricing and auditing

Sales by Region



FY26 Drivers



- **China:**
 - Uscom's **partnership with Foxconn** is expanding into a new high technology Medtech centre in Daxing, an outer suburb of Beijing. Eventually, this centre will provide supply chain and manufacturing capabilities for all Uscom devices worldwide.
 - The **Uscom–SinoPharm partnership** has progressed to the training stage and is expected to begin clinical trials over the next six months, but this penetration has been slowed due to national market uncertainty.
- **SE Asia:** Uscom is currently in discussion with the **Indonesian Government** for the national roll-out of USCOM 1A devices, which will be implemented in approximately 40 paediatric centres across Indonesia, and clinicians will be trained on the use of USCOM 1A's, particularly for the delivery of critical care to children with Dengue sepsis.
- **US:** Our **new partnerships with Premier Health** represent a preferred path to market, and Uscom is planning to support expansion of this major US hospital group to optimise delivery of Uscom technologies into the large US market. Recent legislative developments in the US have further complicated the regulatory and purchasing systems in the US.
- **Europe:** Uscom is **strengthening its footprint** across Europe, with a strong focus on maternal health and advancing solutions for preeclampsia—one of the leading causes of maternal and fetal complications.



Conclusion



FY25 was a year of adaptation for Uscom Limited.

Navigated unpredictable global geopolitics. Trade wars, tariff wars, currency wars, and military conflicts across multiple continents and markets.

Global team has maintained sales focus in preparation for the inevitable recovery

We have developed our devices and planned new technologies to create a new medical technology and revenue platforms for our future.

While the FY25 decrease in sales was disappointing, Uscom devices continue to save lives, change medical practice, and improve our understanding of clinical medicine in a difficult commercial environment, and we can all be proud of that.

Everyone within Uscom, including each investor, is a part of our team and supports our mission to improve global healthcare.

*Professor Rob Phillips
Uscom Chairman and CEO*



Australian Wildlife Conservancy (AWC)

*Australia is the extinction capital of the world
In 15 years the list of threatened species has increased by 36%*

*87% of Australia's mammals,
93% of our reptiles,
94% of our frogs,
and 45% of our bird species
are unique to Australia*



Saving Australia's animals and plants

www.australianwildlife.org

Rob Phillips personally contributes to AWC on behalf of Uscom



Uscom

FY25 AGM Presentation

ASX: UCM

- Resolutions & Voting
- Overview, products and markets
- Milestones
- FY2025 Results
- FY2026 Drivers

Prof. Rob Phillips
Founder and Chairman,
Uscom Limited

Nov 27, 2025